Web Exclusives

The addition of carboplatin increases response in patients with triple-negative breast cancer without pathogenic BRCA1 and BRCA2 mutations. Read More ›

Prolonged use of hormonal contraceptives slightly increases the risk for breast cancer. Read More ›

Intraventricular HER2 CAR T-cell therapy may be an option for patients with HER2+ breast cancer and brain metastasis. Read More ›

In the phase 3 OlympiAD trial, treatment with olaparib significantly improved progression-free survival and reduced the risk for disease progression or death compared with standard chemotherapy in women with HER2-negative, BRCA-mutated metastatic breast cancer. Read More ›

PD-L1 positivity in all cells in patients with breast cancer may be a useful prognostic marker based on a recent meta-analysis. Read More ›

A new analysis shows that there is an ongoing, steady risk for metastatic or distant recurrence of cancer from years 5 to 20 among women with estrogen receptor–positive breast cancer. Read More ›

After accounting for the benefit of pertuzumab, investigators found that >6 cycles of docetaxel did not significantly improve progression-free or overall survival in patients with HER2-positive, metastatic breast cancer. Read More ›

Abemaciclib offers a new option for women with HR-positive, HER2-negative advanced metastatic breast cancer. Read More ›

To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy. Read More ›